Safety and immunogenicity of Clostridium difficile toxoid vaccine in Japanese adults

Osamu Matsuoka, Dhaval M Patel, Shin Sasaki, Hayato Oka, Toru Sasaki, Patricia J Pietrobon, Thelma Laot, Alain Bouckenooghe, Josemund Menezes, Guy de Bruyn, Osamu Matsuoka, Dhaval M Patel, Shin Sasaki, Hayato Oka, Toru Sasaki, Patricia J Pietrobon, Thelma Laot, Alain Bouckenooghe, Josemund Menezes, Guy de Bruyn

Abstract

This was a randomized, placebo-controlled, Phase I/II study conducted in a Japanese cohort to assess the safety and immunogenicity of Clostridium difficile vaccine (the same formulation as that used in the ongoing global Phase III study). Healthy Japanese adults aged 40-75 years were randomized to receive either C. difficile vaccine (N = 67) or placebo (N = 34) by intramuscular injection on Days 0, 7, and 30. Serum IgG specific for toxins A and B was measured by enzyme-linked immunosorbent assay (ELISA) and in vitro functional activity by toxin neutralizing assay (TNA). The seroconversion rate (percentage of participants with a ≥4-fold rise in antibody levels from baseline) was high for both toxin A (ELISA and TNA) and toxin B (ELISA), approaching 100% for each by Day 60. For toxin B assessed by TNA, however, the response was lower, with the seroconversion rate not rising significantly beyond the value of 42.9% seen on Day 14 (44.4% at Day 60). Although the response in the participants who were seronegative at baseline was slower than that in those who were seropositive, seroconversion was seen in nearly all (100%) subjects by Day 60, with the exception of the response to toxin B evaluated using TNA (16-18% on Days 14-60). The proportion of participants with solicited local reactions, solicited systemic reactions, and vaccine-related unsolicited reactions were 67.6%, 19.1%, and 20.6%, respectively. Most of the adverse reactions were mild to moderate in intensity, occurring within 3 days post-vaccination, and resolving by 3-6 days post-vaccination. There were no withdrawals due to adverse events and no serious adverse events. These data confirm the safety and immunogenicity of C. difficile vaccine in Japanese adults.

Keywords: Clostridium difficile; immunogenicity; safety; vaccine.

Figures

Figure 1.
Figure 1.
Participant flow chart.

References

    1. Lessa FC, Mu Y, Bamberg WM, Beldavs ZG, Dumyati GK, Dunn JR, Farley MM, Holzbauer SM, Meek JI, Phipps EC, et al.. Burden of Clostridium difficile infectin in the United States. N Engl J Med. 2015;372(9):825–34. doi:10.1056/NEJMoa1408913.
    1. Kyne L, Farrell FJ, Kelly CP. Clostridium difficile. Gastroenterol Clin North Am. 2001;30(3):753–77, ix-x. doi:10.1016/S0889-8553(05)70209-0.
    1. Vaishnavi C. Clinical spectrum & pathogenesis of Clostridium difficile associated diseases. Indian J Med Res. 2010;131:487–99.
    1. Bauer MP, Notermans DW, van Benthem BH, Brazier JS, Wilcox MH, Rupnik M, Monnet DL, van Dissel JT, Kuijper EJ; ECDIS Study Group . Clostridium difficile infection in Europe: a hospital-based survey. Lancet 2011;377(9759):63–73. doi:10.1016/S0140-6736(10)61266-4.
    1. Mori N, Yoshizawa S, Saga T, Ishii Y, Murakami H, Iwata M, Collins DA, Riley TV, Tateda K. Incorrect diagnosis of Clostridium difficile infection in a university hospital in Japan. J Infect Chemother. 2015;21(10):718–22. doi:10.1016/j.jiac.2015.06.009.
    1. Hikone M, Ainoda Y, Tago S, Fujita T, Hirai Y, Takeuchi K, Totsaku K. Risk factors for recurrent hospital-acquired Clostridium difficile infection in a Japanese university hospital. Clin Exp Gastroenterol. 2015;8:191–6.
    1. Honda H, Yamazaki A, Sato Y, Erik Dubberke. Incidence and mortality associated with Clostridium difficile infection at a Japanese tertiary care center. Anaerobe. 2014;25:5–10. doi:10.1016/j.anaerobe.2013.10.004.
    1. Yoshida J, Kikuchi T, Asano I, Ueno T. Clostridium difficile infection relationship to ward-monthly antimicrobial use density and days of treatment: a three-year study. Jpn J Infect Prev Control. 2016;31(2):92–9. doi:10.4058/jsei.31.92.
    1. Dubberke ER, Olsen MA. Burden of Clostridium difficile on the healthcare system. Clin Infect Dis. 2012;55(Suppl 2):S88–92.
    1. Yasunaga H, Horiguchi H, Hashimoto H, Matsuda S, Fushimi K. The burden of Clostridium difficile-associated disease following digestive tract surery in Japan. J Hosp Infect. 2012;82(3):175–80. doi:10.1016/j.jhin.2012.07.023.
    1. Greenberg RN, Marbury TC, Foglia G, Warny M. Phase I dose finding studies of an adjuvanted Clostridium diffcile toxoid vaccine. Vaccine. 2012;30(13):2245–9. doi:10.1016/j.vaccine.2012.01.065.
    1. Foglia G, Shah S, Luxemburger C, Pietrobon PJ. Clostridium difficile: development of a novel candidate vaccine. Vaccine. 2012;30(29):4307–9. doi:10.1016/j.vaccine.2012.01.056.
    1. de Bruyn G, Saleh J, Workman D, Pollak R, Elinoff V, Fraser NJ, Lefebvre G, Martens M, Mills RE, Nathan R, et al.. Defining the optimal formulation and schedule of a candidate toxoid vaccine agrainst Clostridium difficile infection: A randomized Phase 2 clinical trial. Vaccine. 2016;34(19):2170–8. doi:10.1016/j.vaccine.2016.03.028.
    1. Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Statistics in Medicine. 1998;17(8):857–72. doi:10.1002/(SICI)1097-0258(19980430)17:8%3c857::AID-SIM777%;2-E.
    1. Sheldon E, Kitchin N, Peng Y, Eiden J, Gruber W, Johnson E, Jansen KU, Pride MW, Pedneault L. A phase 1, placebo-controlled, randomized study of the safety, tolerability, and immunogenicity of a Clostridium difficile vaccine administered with or without aluminum hydroxide in healthy adults. Vaccine. 2016;34(18):2082–91. doi:10.1016/j.vaccine.2016.03.010.
    1. Bezay N, Ayad A, Dubischar K, Firbas C, Hochreiter R, Kiermayr S, Kiss I, Pinl F, Jilma B, Westritschnig K. Safety, immunogenicity and dose response of VLA84, a new vaccine candidate against Clostridium difficile, in healthy volunteers. Vaccine. 2016;34(23):2585–92. doi:10.1016/j.vaccine.2016.03.098.
    1. Burke KE, Lamont JT. Clostridium difficile infection: a worldwide disease. Gut Liver. 2014;8(1):1–6.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner